

Supplementary Table 1.

Significant Compounds Following Supervised Pharmacologic Analysis of BRAF(V600E) Mutation in NCI60 Cancer Cell Lines^a.

NSC Number	Name	Nominal <i>p</i> value	FDR ^b	T-score
354462	Hypothemycin ^c	1.66E-11	7.27E-07	-8.60701
706829	1,6-Bis[4-(4-aminophenoxy)phenyl]diamantane	8.10E-11	1.78E-06	-8.24454
678518	Protein: LF ^c	1.17E-07	1.71E-03	-6.46505
658874		3.12E-07	2.74E-03	-5.95796
669995		3.12E-07	2.74E-03	-5.88385
701104		5.07E-07	3.71E-03	-5.76488
600391	Antibiotic 2-79-A	3.17E-06	1.81E-02	-5.23291
656082		3.72E-06	1.81E-02	-5.38308
706031		9.09E-06	3.99E-02	-4.93085
165572	Pyrido[3,2-g]quinoline-2,5,8,10(1H,9H)-tetrone	1.20E-05	4.78E-02	-4.86143
661940	2-(2-chloroethoxy)naphthazarin	1.58E-05	5.76E-02	-4.77118
708551		2.34E-05	7.91E-02	-4.65508
644211	Chlorodestruxin	2.67E-05	8.37E-02	-4.63522
708550		3.74E-05	1.03E-01	-4.51708
679828	2-(2-Amino-3-methoxyphenyl)-chromen-4-one (PD98059) ^c	3.78E-05	1.03E-01	-4.52208
602617	Benzo[g]quinoxaline-5,10-dione	4.43E-05	1.03E-01	-4.46683
661413	2-(2-Methoxyethoxy)naphthazarin	4.58E-05	1.03E-01	-4.45647
664213	Chlorotetrangulol	4.66E-05	1.03E-01	-4.46837
674092	Quinoline-4-carboxamide,N,N'-[(1,4-piperazinediyl)bis(3,1-propanediyl)]bis(2-phenyl) dihydrochloride	4.70E-05	1.03E-01	-4.44895
322921	Pibenzimol-HCl; Hoechst dye	5.01E-05	1.05E-01	-4.42970
661416	2-(2-(2-Methoxyethoxy)ethoxy)naphthazarin	8.10E-05	1.50E-01	-4.30846
661941	2-(3-chloropropoxy)naphthazarin	8.20E-05	1.50E-01	-4.28875
644902	Benzo[b]naphtho[2,3-d]furna-6,11-diome, 4-chloro-3-hydroxy	9.69E-05	1.67E-01	-4.23074
622580		1.03E-04	1.67E-01	-4.28922
658450	2-Acetamido-6-methyl-8-hydroxy-1,4-naphthaquinone	1.11E-04	1.74E-01	-4.18882
622582		1.17E-04	1.77E-01	-4.24785
685981	1,4-Butanediamine,N,N'-bis[(2-naphthalenyl)methyl-N,N'-bis[3-[(trifluoroacetyl)amino]propyl]	1.21E-04	1.77E-01	-4.20039
686324	1-Methyl-3-(4-[2-dimethylaminoethoxy]phenyl)-2-phenylindolizine	1.25E-04	1.77E-01	-4.15329
697177		1.32E-04	1.81E-01	-4.18153
622688	3H-1,2,4-Dithiazole-5-amine,3-[2-(diethoxyethyl)imino-N,N-dimethyl-,hydrobromide	1.53E-04	2.03E-01	-4.09139
090829		1.78E-04	2.19E-01	-4.04392
674085		1.80E-04	2.19E-01	-4.04030

626482	1,5,10-Trihydroxy-7-methoxy-3-methyl-1H-naphtho[2,3-c]pyran-6,9-dione	1.85E-04	2.19E-01	-4.03264
661193	Propanamide, 2-[4-[[4-chlorophenyl]carbonyl]-2-chlorophenoxy]-2-methyl-	2.08E-04	2.39E-01	-3.99526
625502	4-Morpholinecarbodithioic acid, antimony complex	2.12E-04	2.39E-01	-3.98909
676180		2.26E-04	2.42E-01	-3.97585
678883	Pyrimidin-2-amine,4-(5-chloro-2-hydroxyphenyl)-6-phenyl-N-(phenylmethylene)-	3.36E-06	1.81E-02	5.21642
671526	Toxin-.delta.53L	6.12E-05	1.22E-01	4.37744
704408		1.02E-04	1.67E-01	4.23034
094889	Gardenin A	1.81E-04	2.19E-01	4.05136
676495		2.23E-04	2.42E-01	3.98056

^aCompounds in black font demonstrated significantly greater potency against the BRAF(V600E) cell line class; those in red font exhibited significantly less potency (e.g., the BRAF(V600E) class was resistant to these compounds).

^bFDR = false discovery rate (q value), which was set at 0.25 (see Methods; Reference: Benjamini, Y. and Hochberg, Y., Journal of the Royal Statistical Society. Series B (Methodological), 1995. 57(1): p. 289-300).

^cCompounds known to inhibit MEK.